Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

Canada NewsWire February 13, 2017

Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

PR Newswire Asia January 23, 2017

Airline Industry Brief Examines the "Three-P" Approach to Sector Growth in 2017: Passengers, Payments and Profitability

PR Newswire Asia January 23, 2017

Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

Canada NewsWire January 5, 2017

Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

Canada NewsWire December 15, 2016

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

Canada NewsWire December 13, 2016

Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

Canada NewsWire December 5, 2016

Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

Canada NewsWire November 17, 2016

Resverlogix Announces Annual and Special Meeting of Shareholders

Canada NewsWire October 6, 2016

Resverlogix Announces Annual and Special Meeting of Shareholders

PR Newswire October 6, 2016

Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease

Canada NewsWire October 4, 2016

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

Canada NewsWire September 14, 2016

Resverlogix Announces Participation in Upcoming Conferences

Canada NewsWire September 12, 2016

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Canada NewsWire August 29, 2016

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

PR Newswire August 29, 2016

Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

PR Newswire Asia August 11, 2016

Resverlogix Files 2016 Year-End Disclosure Documents

Canada NewsWire July 27, 2016

Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

Canada NewsWire July 21, 2016

Resverlogix Announces Corporate Update Webcast

PR Newswire June 9, 2016

Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016

Canada NewsWire June 2, 2016